Literature DB >> 9210669

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

M A Visalli1, S Bajaksouzian, M R Jacobs, P C Appelbaum.   

Abstract

In the first part of this study, agar dilution MICs were used to test the activities of trovafloxacin, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, clinafloxacin, ceftazidime, and imipenem against 458 gram-negative nonfermenters. The overall respective MICs at which 50% of isolates are inhibited (MIC50s) and MIC90s were as follows: trovafloxacin, 1.0 and 16.0 microg/ml; ciprofloxacin, 2.0 and 16.0 microg/ml; ofloxacin, 2.0 and 32.0 microg/ml; levofloxacin, 1.0 and 16.0 microg/ml; sparfloxacin, 1.0 and 16.0 microg/ml; clinafloxacin, 0.5 and 4.0 microg/ml; ceftazidime, 8.0 and 128.0 microg/ml; imipenem, 2.0 and 256.0 microg/ml. Clinafloxacin was the most active of all the quinolones tested. The MIC90s of trovafloxacin were < or = 4.0 microg/ml for Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Flavobacterium odoratum, and Chryseobacterium meningosepticum; trovafloxacin MIC90s were < or = 2.0 microg/ml for Moraxella spp., Pseudomonas stutzeri, and Chryseobacterium indologenes-C. gleum. Of the other quinolones tested, the MICs of sparfloxacin and levofloxacin were lower than those of ciprofloxacin and ofloxacin. High ceftazidime MICs (> or = 32.0 microg/ml) were observed for all nonfermentative species tested. Although for the majority of strains tested imipenem MICs were < or = 8.0 microg/ml, high imipenem MICs were observed for many species, especially S. maltophilia, Burkholderia cepacia, F. odoratum, and Chryseobacterium meningosepticum. For Alcaligenes xylosoxidans strains, the MICs of all compounds were generally a few dilutions lower than those for Alcaligenes faecalis-A. odorans. Time-kill studies with five strains revealed that trovafloxacin and all quinolones yielded more rapid time-kill kinetics than ceftazidime and imipenem. Synergy testing by checkerboard titrations of 286 strains with trovafloxacin combined with ceftazidime, amikacin, and imipenem revealed fractional inhibitory concentration (FIC) indices in the range indicating synergism (< or = 0.5) for 81, 41, and 40 strains, respectively, and FIC indices indicating additivity or indifference (> 0.5 to 4.0) for 205, 245, and 246 strains, respectively. No FIC indices indicating antagonism (> 4.0) were observed. Synergy between trovafloxacin and ceftazidime was found for 32 of 36 S. maltophilia strains. Time-kill studies with 20 strains showed that for most strains for which FIC indices were in the range indicating additivity or indifference, FIC indices indicated synergy by the time-kill method. Synergy was particularly noticeable for S. maltophilia strains with combinations of ceftazidime and trovafloxacin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210669      PMCID: PMC163943     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Antibiotic resistance pattern of Flavobacterium meningosepticum.

Authors:  A Raimondi; F Moosdeen; J D Williams
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

2.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Susceptibility of Pseudomonas paucimobilis to 24 antimicrobial agents.

Authors:  D L Smalley; V R Hansen; V S Baselski
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

4.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

5.  Comparative activity of imipenem, ceftazidime and cefotaxime against Acinetobacter calcoaceticus.

Authors:  E Bergogne-Berezin; M L Joly-Guillou
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

6.  In vitro susceptibility of Acinetobacter species to various antimicrobial agents.

Authors:  K V Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

7.  Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome.

Authors:  P C Appelbaum; S K Spangler; L Sollenberger
Journal:  J Antimicrob Chemother       Date:  1986-12       Impact factor: 5.790

8.  Comparative in-vitro activity of ciprofloxacin against non-fermenters.

Authors:  M O Husson; D Izard; L Bouillet; H Leclerc
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

Review 9.  In vitro susceptibilities of nonfermentative gram-negative bacilli other than Pseudomonas aeruginosa to 32 antimicrobial agents.

Authors:  R J Fass; J Barnishan
Journal:  Rev Infect Dis       Date:  1980 Nov-Dec

10.  Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.

Authors:  P C Appelbaum; S K Spangler; T Tamarree
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

View more
  22 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

3.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

4.  Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.

Authors:  Kim Credito; Gengrong Lin; Laura Koeth; Michael A Sturgess; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

5.  Comparative activities of clinafloxacin against gram-positive and -negative bacteria.

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

6.  In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus.

Authors:  Dong-Min Kim; Yong Lym; Sook Jin Jang; Hulin Han; Young Gi Kim; Choon-Hae Chung; Soon Pyo Hong
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

8.  Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Authors:  E Gradelski; L Valera; D Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

10.  Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.